Roth Capital Downgrades vTv Therapeutics (VTVT) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- US stock futures steady after tech slump; investors focus on Middle East tensions
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Marvell shares jump after giving Google warrants amid custom chip deal
Northland Capital Markets Downgrades vTv Therapeutics (VTVT) to Market Perform
April 10, 2018 9:01 AM EDTNorthland Capital Markets downgraded vTv Therapeutics (NASDAQ: VTVT) from Outperform to Market Perform with a price target of $3.00 (from $28.00).
For an analyst ratings summary and ratings history on vTv Therapeutics click here. For more ratings news on vTv Therapeutics click here.
Shares of vTv Therapeutics closed at $3.26 yesterday.
... MoreUPDATE: Seaport Global Securities Downgrades vTv Therapeutics (VTVT) to Neutral
April 10, 2018 7:11 AM EDT(Updated - April 10, 2018 8:19 AM EDT)
(updated to add analyst comment)
Seaport Global Securities downgraded vTv Therapeutics (NASDAQ: VTVT) from Buy to Neutral with a price target of $1.00 (from $14.00).
Analyst Corey Davis comments "The first of two Phase 3 STEADFAST studies... More
Piper Jaffray Downgrades vTv Therapeutics (VTVT) to Neutral
April 10, 2018 3:45 AM EDTPiper Jaffray downgraded vTv Therapeutics (NASDAQ: VTVT) from Overweight to Neutral with a price target of $4.00 (from $24.00).
Analyst Charles Duncan comments "Given VTVT shares trading range from mid-Jan ~$8 to current ~$4, we believe that this result is not a big surprise to investors. However,... More
Stifel Downgrades vTv Therapeutics (VTVT) to Hold
April 10, 2018 3:43 AM EDTStifel downgraded vTv Therapeutics (NASDAQ: VTVT) from Buy to Hold with a price target of $1.00 (from $12.00).
Analyst Alex Schwartz comments "...we are adjusting our Azeliragon probability-of-success from 50% to 0%. We see value in vTv Therapeutics' two underlying diabetes assets that each possess... More
